Clinical Trial: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT – 2)

Clinical Trial: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT – 2)  

Sponsor and Collaborators

Bristol-Myers Squibb

Abbott Biotherapeutics

ClinicalTrials.gov Identifier

NCT01239797